Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Seeger

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Cancer|July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer GroupJ D Frost, J A Hank, G H Reaman, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary reportR P Castleberry, J Pritchard, P Ambros, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group studyJ M Maris, M J Weiss, C Guo, et al.
Cancer|July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer GroupJ D Frost, J A Hank, G H Reaman, et al.
British Journal of Cancer|June 3, 2015
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group studyL L Wang, R Teshiba, N Ikegaki, et al.
Oncogene|January 24, 2012
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaE L Carpenter, E A Haglund, E M Mace, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
The International Neuroblastoma Risk Groups (INRG): a preliminary reportR P Castleberry, J Pritchard, P Ambros, et al.
Pageof 16